Syros Pharmaceuticals Performance
| SYRSDelisted Stock | USD 0.06 0.01 10.35% |
The entity has a beta of 0.56, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Syros Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Syros Pharmaceuticals is expected to be smaller as well. At this point, Syros Pharmaceuticals has a negative expected return of -1.32%. Please make sure to validate Syros Pharmaceuticals' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Syros Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Syros Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in June 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 170.6 M |
Syros |
Syros Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 17.00 in Syros Pharmaceuticals on February 11, 2025 and sell it today you would lose (10.85) from holding Syros Pharmaceuticals or give up 63.82% of portfolio value over 90 days. Syros Pharmaceuticals is currently does not generate positive expected returns and assumes 20.5746% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Syros, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Syros Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syros Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Syros Pharmaceuticals, and traders can use it to determine the average amount a Syros Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0642
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SYRS |
Estimated Market Risk
| 20.57 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Syros Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Syros Pharmaceuticals by adding Syros Pharmaceuticals to a well-diversified portfolio.
Syros Pharmaceuticals Fundamentals Growth
Syros Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Syros Pharmaceuticals, and Syros Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Syros Pink Sheet performance.
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (288.92) % | ||||
| Current Valuation | 3.6 M | ||||
| Shares Outstanding | 26.83 M | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 10.65 X | ||||
| Price To Sales | 13.91 X | ||||
| Revenue | 9.94 M | ||||
| EBITDA | (157.19 M) | ||||
| Cash And Equivalents | 244.48 M | ||||
| Cash Per Share | 12.09 X | ||||
| Total Debt | 62.08 M | ||||
| Debt To Equity | 0.49 % | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (109.71 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Total Asset | 168.17 M | ||||
| Retained Earnings | (722.81 M) | ||||
| Current Asset | 85.51 M | ||||
| Current Liabilities | 9.57 M | ||||
About Syros Pharmaceuticals Performance
Assessing Syros Pharmaceuticals' fundamental ratios provides investors with valuable insights into Syros Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Syros Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.Things to note about Syros Pharmaceuticals performance evaluation
Checking the ongoing alerts about Syros Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Syros Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Syros Pharmaceuticals is not yet fully synchronised with the market data | |
| Syros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syros Pharmaceuticals has high historical volatility and very poor performance | |
| Syros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Syros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.94 M. Net Loss for the year was (164.57 M) with loss before overhead, payroll, taxes, and interest of (88.25 M). | |
| Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Syros Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Syros Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Syros Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Syros Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Syros Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Syros Pharmaceuticals' pink sheet. These opinions can provide insight into Syros Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Syros Pink Sheet
If you are still planning to invest in Syros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syros Pharmaceuticals' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |